Matt Callahan
Board Member
Orthocell
Australia
Biography
Mr Callahan is an experienced life sciences executive based in Philadelphia. He is the founding CEO of iCeutica Inc and a co-inventor of some of the technologies that comprise the SoluMatrix Fine Particle Technology™ platform that iCeutica uses to develop new pharmaceuticals. iCeutica has developed two products to date that have received FDA approval, has 1 pending approval and 2 products in late stage development. He has more than 18 years legal, IP and investment management experience and is also a director of Glycan Bioscience LLC and founding CEO of Churchill Pharma. Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, clean technology and other sectors and was General Manager and General Counsel with Australian listed technology and licensing company ipernica (now Nearmap ASX:NEA), where he was responsible for the licensing programs that generated more than $120M in revenue.
Research Interest
Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology Pharmaceutical Nanotechnology Pharmaceutical Technology Pharmaceutical Manufacturing Pharmaceutical Engineering Drug Delivery Technologies Medical Devices Drug Regulatory Affairs Pharmaceutical Management
